Tecan Group AG

Tecan appoints Dr. Stefan Traeger to the Management Board

Tecan Group AG / Tecan Group AG : Tecan appoints Dr. Stefan Traeger to the Management Board . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Männedorf, Switzerland, February 28, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has appointed Dr. Stefan Traeger as a member of the Management Board. As Head of the Life Sciences Business division Stefan Traeger will be responsible for the Group's global end-customer business. He will take up his new post at Tecan on July 1, 2013. This position has been vacant since summer 2012.

Stefan Traeger has extensive domain experience in a variety of management positions in the life science industry. Since late 2007, he served as Managing Director of Leica Microsystems CMS GmbH and as Vice President and General Manager of Leica's global Life Science Division. Prior to this, Stefan Traeger held a number of positions with increasing management responsibility in various areas within the Carl Zeiss Group between 2000 and the end of 2007, most recently as Director Strategic Business Development of Carl Zeiss Meditec and Managing Director of Carl Zeiss SMT Ltd.

Tecan CEO David Martyr commented: "During our time together at Leica Microsystems, I came to know Stefan Traeger as a strong leader who has achieved significant successes. He resolutely aligned the Life Science division, the largest division at Leica Microsystems, to the needs of the market, increased sales considerably and raised profitability significantly. He also very successfully integrated two acquired companies into the existing business. We are delighted that Stefan Traeger will now bolster the Tecan management team in this vital position."

Stefan Traeger holds a PhD from the University of Hannover, Germany, and an MBA from Purdue University. He is 45 years old and a German citizen.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).

For further information:
Tecan Group

Martin Brändle

Head of Corporate Communications & Investor Relations

Tel. [phone]

Fax [phone]

[e-mail]

www.tecan.com

Press Release (PDF)

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Tecan Group AG via Thomson Reuters ONE

HUG#1681569

--- End of Message ---

Tecan Group AG
Seestrasse 103 Männedorf Switzerland

ISIN: CH0012100191;